Effectiveness and Safety of CCoat Intra-Articular Injections in Mild to Moderate Knee Osteoarthritis
Key facts
- Who runs it
- Lipo-Sphere
- Where
- Israel3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 125 people enrolled
- Started
- 16 Mar 2023
- Ended
- 1 Jun 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- CCoat
- Record updated
- 27 February 2026
Who can take part
- Age
- 30 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- Subject has signed and dated the informed consent form
- Age ≥30 and ≤ 85 years old
- Pain in the intended study knee with an average VAS score (active) of ≥3 over the last week before screening
- Degenerative changes in the intended study knee that can be categorized as grade I -III- Kellgren Lawrence based upon standing anterior- posterior and lateral radiographsof the knee
- Body Mass Index (BMI) between 18.5 and 38
- A negative urine pregnancy test female patient with childbearing potential at Visit 1 prior to intra-articular injection of AqueousJoint
- If female, the subject must be either postmenopausal, OR permanently surgically sterile OR for women of childbearing potential using at least 2 methods of birth control that are effective from at least 30 days before Visit 1 through visit 26w (26 weeks post injection)
- Are willing or able to comply with procedures required in this protocol
Who cannot take part
- History of significant knee trauma or previous surgery of the intended study knee within the last 3 months preceding the screening
- Intra-articular injection to the intended study knee within 3 months before Screening
- Intake of chronic pain medications (especially opioid pain relievers) without an option to pause for the period of the study
- Chemotherapy and/or radiation in the past 12 months
- Participation in other clinical trials within 60 days to before the study or concurrent with the study
- History of Psoriatic Arthritis, Rheumatoid Arthritis, or any other inflammatory condition associated with arthritis
- Any known history of intra-articular or osseous infection of the index knee
- Any evidence of active infection anywhere in the body. Urinary Tract Infection (UTI) patients can be included following antibiotic treatment, provided that two consecutive cultures are negative (taken within at least 2 weeks of each other)
- Any known history of inflammatory arthropathy or crystal-deposition arthropathy
- Any known systemic cartilage and/or bone disorder, such as but not limited to, chondrodysplasia or osteogenesis imperfecta
- Known history of a severe allergic reaction
- History of any significant systemic disease, such as but not limited to: HIV, hepatitis, HTLV, syphilis, and coagulopathies
- Known insulin dependent diabetes mellitus
- Osteoarthritis of the index knee graded 4 according to the Kellgren-Lawrence Grading
- Pain in both knees with a VAS score of ≥5
- Significant instability of the index knee
- Malalignment more than 10 degrees varus OR 10 degrees valgus according to standing X-ray
- Wound in the area of the intended study knee
- Any known tumor of the index knee
- Body Mass Index (BMI) > 38
- Active malignances, excluding BCC
- Patient who is pregnant or intends to become pregnant during the study
- A Known substance or alcohol abuse
- Unable to undergo X-ray
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the Efficacy and Safety of CCoat Intra-Articular Injection in Mild to Moderate Knee Osteoarthritis.
Read full original descriptionShow less
The main questions it aims to answer are:
* To demonstrate superior efficacy of CCoat administered via intra-articular injection versus placebo during the study period. * To evaluate the efficacy of two different concentrations of CCoat, administered via single IA injection as compared to control group (placebo) One IA injection of CCoat or Placebo will be injected to participants' knee. Follow up will take place up to six months. * To evaluate the safety of the repeated CCoat injection administered at six months.
The 2 groups in the trial
- Group 1 (Control)Placebo, for comparison
1 IA injection of 4 ml Normal Saline solution.
Treatment: CCoat
- Group 2 (Study)Treatment being tested
1 IA injection of 4 ml CCoat
Treatment: CCoat
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Effectiveness and Safety of CCoat Intra-Articular Injections in Mild to Moderate Knee Osteoarthritis: Prospective, Placebo Controlled, Randomized, Double-Blinded Study
- Record updated
- 27 February 2026